We monitored their aminotransferase levels, Child-Pugh score, MELD score, HBeAg, HBV DNA level and change of ascites at 3 months, 6

months, 9 months, and 12 months after antiviral treatment. We defined clinical responder as patients with a minimum of 1 point of reduction of Child-Pugh score and decreased ascites or patients with more than 2 points of reduction of Child-Pugh score and virological responder as patients with more than reduction of 2 log10 copies of HBV DNA. Results: Eighty (65%) patients were defined as responder after 12 months of antiviral treatment. Baseline ALT, JNK inhibitors library HBV DNA and positive rate of HBeAg of responder are higher than that of non-responder. Patients in response group had the significant improvement of Child-Pugh score

(−1.41 ± 1.90, P < 0.001), the remarkable reduction in HBV DNA level (−3.30 ± 1.68 log10 copies/mL, P < 0.001), the decrease of ascites (36.3%, P < 0.001) compared to the findings before treatment. Serum HBV DNA level at 3 months after treatment showed significant difference between response group (−2.74 ± 1.5 log10 copies/mL) and non-response group (−0.31 ± 1.0 log10 copies/mL) (P < 0.001), whereas serum HBV DNA undetectable rate, seroconversion rate and ALT normalization did not. Conclusion: It is possible to predict the clinical and virological response in patients with hepatitis B virus-related liver cirrhosis by checking the reduction in serum HBV DNA level at 3 months after treatment. Key Word(s): 1. Hepatitis B virus; 2. Liver Roflumilast Mitomycin C mw cirrhosis; 3. Antiviral

treatment; 4. Treatment predictor; Presenting Author: MANEESHA BHULLAR Additional Authors: JOHN YAMBA Corresponding Author: MANEESHA BHULLAR Affiliations: Royal Melbourne Hospital; Ballarat Base Hospital Objective: Peginterferon (PEG-IFN) alpha in combination with ribavirin (RBV) represents the most optimal therapy for chronic hepatitis C. Despite its great efficacy, interferon therapy is associated with a spectrum of side effects. Pulmonary toxicities are a rare side effect which may include interstitial pneumonitis, sarcoidosis, pleuritis, bronchiolitis obliterans organizing pneumonia (BOOP), and exacerbation of asthma. Interstitial pneumonitis is a rare but rapidly progressing and potentially fatal adverse event that has been described. This review describes the classification, epidemiology, natural history, diagnostic criteria and management of Interferon-related interstitial pneumonitis and includes an illustrative patient. Methods: A systematic review of the literature using relevant databases was performed to ascertain patients with chronic hepatitis C who developed interstitial pneumonitis on interferon-based therapy, either as a standalone therapy or in combination with ribavirin.